Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 9/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1948963 | 0.79 | IDO1 (0.53) | IDO1 | |
| SCHEMBL2880191 | 0.76 | LMNA (0.54) | RXFP1BRD9NAMPTMETAP1LMNA | |
| SCHEMBL28444082 | 0.76 | CHRM3 (0.52) | BRD9LMNA | |
| SCHEMBL6365954 | 0.75 | ALDH1A1 (0.45) | IDO1RXFP1TRPV1BRD9NAMPT | |
| SCHEMBL1950652 | 0.75 | BRD9 (0.42) | IDO1RXFP1TRPV1BRD9METAP1 | |
| SCHEMBL29773351 | 0.75 | TRPV1 (0.43) | IDO1RXFP1TRPV1BRD9METAP1 | |
| SCHEMBL4414634 | 0.75 | LMNA (0.48) | IDO1RXFP1TRPV1BRD9METAP1 | |
| SCHEMBL22356644 | 0.74 | RXFP1 (0.43) | IDO1RXFP1TRPV1BRD9METAP1 | |
| SCHEMBL9109986 | 0.74 | CYP17A1 (0.41) | NAMPT | |
| SCHEMBL2940952 | 0.74 | GAA (0.51) | RXFP1BRD9METAP1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140323740-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-10-30 | — | — | US | disclosed |
| US-8748469-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748469-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2291187-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009132238-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009132238-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323740-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885RXFP1 716/4885TRPV1 3027/4885 |
| US-20110136796-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885RXFP1 716/4885TRPV1 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.